503B vs 503A GLP-1 Providers: A Patient's Comparison Guide
Price verification — October 26, 2026
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
- Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
- Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
- Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
- Sesame annual-commitment terms: Official source.
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due. Compounded GLP-1 products are not FDA-approved. Their availability, lawful compounding circumstances and product claims require separate verification. FDA policy.
The FDA's 503B Bulks List proposal is making pharmacy classifications relevant to every GLP-1 patient. Here's what you need to understand.
Quick Comparison
| 503A Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Regulation | State pharmacy board | FDA (direct) |
| Prescription | Patient-specific required | Not always needed |
| Scale | Individual orders | Large-batch permitted |
| FDA proposal impact | Not directly targeted | Directly affected |
| Quality standards | USP 795/797 | cGMP (pharmaceutical-grade) |
Why This Matters Right Now
The FDA proposed excluding GLP-1 active ingredients from the 503B Bulks List on April 30, 2026. If finalized, 503B facilities lose the ability to compound semaglutide, tirzepatide, and liraglutide at scale. 503A pharmacies operate under different authority and aren't directly targeted by this specific proposal.
How to Find Out Your Pharmacy Type
- Ask your provider directly: "Is my medication compounded by a 503A or 503B pharmacy?"
- Check the FDA's outsourcing facility registry — 503B facilities must be listed
- Look for "cGMP" language — this typically indicates a 503B facility
Wellorithm · from $147/mo
Compounded medications are not FDA-approved. Paid link
$146/mo sema
Try Gala GLP-1 instead → Paid linkCompounded medications are not FDA-approved.
from $129/mo
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
The Bottom Line
If your provider uses a 503A pharmacy, the FDA's current proposal has less immediate impact on your prescription. If they use a 503B facility, start planning for alternatives now — the regulatory timeline gives you months, not days. Either way, brand-name options at lower price points (oral Wegovy at $149) provide a safety net.
Sources
- FDCA Sections 503A and 503B
- FDA proposed rule, April 30, 2026